SPONSOR

Fondazione IRCCS Policlinico San Matteo di Pavia

Total Trials

Recruiting

Phases

N/A

Conditions studied: Pressure Ulcers in the Neonatal Population Respiratory Distress Syndrome RDS Preterm Birth Heart Failure Non Small Cell Lung Cancer Metastatic Refractory Cardiac Arrest ATTR Amyloidosis Reconstructive Surgery Head and Neck Microvascular Free Flap Immune Checkpoint Inhibitors-induced Colitis

Fondazione IRCCS Policlinico San Matteo di Pavia is a clinical research sponsor with 16 registered studies on ClinicalTrials.gov, of which 16 are actively recruiting participants. Research covers conditions including Pressure Ulcers in the Neonatal Population, Respiratory Distress Syndrome RDS, Preterm Birth, Heart Failure.

Studies span multiple clinical phases, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — Fondazione IRCCS Policlinico San Matteo di Pavia

How many clinical trials has Fondazione IRCCS Policlinico San Matteo di Pavia sponsored?

ClinicalMetric currently tracks 16 clinical trials sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia, of which 16 are actively recruiting participants. These trials cover conditions including Pressure Ulcers in the Neonatal Population, Respiratory Distress Syndrome RDS, Preterm Birth. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does Fondazione IRCCS Policlinico San Matteo di Pavia research focus on?

Fondazione IRCCS Policlinico San Matteo di Pavia clinical trials span Pressure Ulcers in the Neonatal Population, Respiratory Distress Syndrome RDS, Preterm Birth, Heart Failure, Non Small Cell Lung Cancer Metastatic, and additional conditions. Sponsor focus areas evolve as trials complete and new programs launch.

How do I participate in a Fondazione IRCCS Policlinico San Matteo di Pavia clinical trial?

To participate in a Fondazione IRCCS Policlinico San Matteo di Pavia trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Fondazione IRCCS Policlinico San Matteo di Pavia trials with current recruitment status updated daily.

Fondazione IRCCS Policlinico San Matteo di Pavia

Frequently Asked Questions — Fondazione IRCCS Policlinico San Matteo di Pavia

Clinical Trials by Fondazione IRCCS Policlinico San Matteo di Pavia

Italian Validation of a Pressure Injury Risk Assessment Scale (Braden QDS) in the Neonatal Intensive Care Unit

Early Prediction of Lung Injury in Preterm Infants Score

Registry of Pavia Chronic Heart Failure Patients-observational Study

First-line Therapy With Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metatastatic NSCLC (NICReWo Trial)

Feasibility Study on a Prehospital Extracorporeal CardioPulmonary Resuscitation in the Pavia's Province.

The Italian Transthyretin Amyloidosis Web-Network

Postoperative Management of Patients Undergoing Head and Neck Microvascular Free Flap Reconstructive Surgery: is Admission to an Intensive Care Unit Necessary?

Long-term Follow-up of Checkpoint Inhibitors-induced Ileo-colitis

GEN-FPF: Genetic Exploration of Familial Pulmonary Fibrosis

Surgical vs Endoscopic Treatments as ImmunoModulating Interventions in High-Risk Acute Calculous Cholecystitis

ACU_Knee: Role of Acupuncture in Knee Prosthetic Surgery

Unveiling the Germline Predisposition to Myeloproliferative Neoplasms

Coping and Attachment in Pediatric Oncohematology

A Comprehensive Register Of Lymphoproliferative Disorders (ReLy)

Natural History of Eosinophilic Esophagitis in Adult and Pediatric Population

Dissecting Tumour MicroenvirOnment in Solid Paediatric Tumour to Improve Adoptive Cell Therapy